Howard Kim

About the Author Howard Kim


BMO Capital Keeps Their Buy Rating on Checkmate Pharmaceuticals (CMPI)

In a report released today, Do Kim from BMO Capital maintained a Buy rating on Checkmate Pharmaceuticals (CMPI), with a price target of …

TCR2 Therapeutics (TCRR) Receives a Buy from BMO Capital

In a report released today, Do Kim from BMO Capital maintained a Buy rating on TCR2 Therapeutics (TCRR), with a price target of …

Analysts Are Neutral on These Financial Stocks: Nasdaq (NDAQ), Lazard (LAZ)

Analysts fell to the sidelines weighing in on Nasdaq (NDAQ) and Lazard (LAZ) with neutral ratings, indicating that the experts are neither bullish …

FedNat Holding Company (FNHC) Gets a Hold Rating from Raymond James

In a report released today, Charles Peters from Raymond James reiterated a Hold rating on FedNat Holding Company (FNHC). The company’s shares closed …

Blueprint Medicines (BPMC) Gets a Buy Rating from Raymond James

In a report issued on April 10, Dane Leone from Raymond James maintained a Buy rating on Blueprint Medicines (BPMC). The company’s shares …

Corus Entertainment (CJREF) Gets a Buy Rating from Canaccord Genuity

In a report issued on April 9, Aravinda Galappatthige from Canaccord Genuity maintained a Buy rating on Corus Entertainment (CJREF), with a price …

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Repare Therapeutics (RPTX), Clovis Oncology …

H.C. Wainwright Sticks to Their Buy Rating for GlycoMimetics (GLYC)

In a report released today, Edward White from H.C.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts